AG0301-COVID19

AG0301-COVID19 Uses, Dosage, Side Effects, Food Interaction and all others data.

AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA vaccine product. On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472).

Trade Name AG0301-COVID19
Generic AG0301-COVID19
Type
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
AG0301-COVID19
AG0301-COVID19

Innovators Monograph

You find simplified version here AG0301-COVID19


*** Taking medicines without doctor's advice can cause long-term problems.
Share